PMID: 8190448Jun 1, 1994Paper

Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis

Obstetrics and Gynecology
J A McGregorR S Gibbs

Abstract

To evaluate the efficacy and safety of ampicillin-sulbactam (3 g every 6 hours) in patients with pelvic inflammatory disease or postpartum endometritis using a randomized, comparative, multicenter study of parallel design. Eligible patients with pelvic inflammatory disease were randomized to receive either ampicillin-sulbactam or cefoxitin (2 g every 6 hours) plus doxycycline (100 mg every 12 hours). Those with endometritis were randomized to ampicillin-sulbactam or clindamycin (900 mg every 8 hours) plus gentamicin (1.5 mg/kg every 8 hours). In the ampicillin-sulbactam group, chlamydia-positive patients also received oral doxycycline. For pelvic inflammatory disease, the clinical response rates (cure or improvement) were 85.5% (47 of 55) and 89.6% (43 of 48) in the ampicillin-sulbactam and cefoxitin and doxycycline groups, respectively (chi 2 = 0.10, P = .76). For endometritis, the clinical response rates were 88.7% (141 of 159) and 90.8% (139 of 153) in the ampicillin-sulbactam and clindamycin and gentamicin groups, respectively (chi 2 = 0.15, P = .70). The percentages of patients with pelvic inflammatory disease who had adverse experiences were not significantly different in the cefoxitin and doxycycline group (47% [29 of 62...Continue Reading

Citations

Dec 18, 2004·Archives of Gynecology and Obstetrics·Stavros SifakisEugenios Koumantakis
Feb 3, 2012·Current Infectious Disease Reports·Richard L Sweet
Mar 8, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cheryl K Walker, Harold C Wiesenfeld
Jan 10, 2012·Infectious Diseases in Obstetrics and Gynecology·Richard L Sweet
Jan 1, 1995·Infectious Diseases in Obstetrics and Gynecology·K L Williams, J G Pastorek Ii
Jul 23, 2009·Expert Opinion on Drug Metabolism & Toxicology·Alex P Betrosian, Emmanuel E Douzinas
Nov 28, 2013·Infectious Disease Clinics of North America·Caroline Mitchell, Malavika Prabhu
Jun 2, 2012·Contraception·Jennefer A RussoLaura Gil
Jun 10, 2008·International Journal of Antimicrobial Agents·Hartmut M Lode
Apr 30, 2015·The Cochrane Database of Systematic Reviews·A Dhanya MackeenLinda Speer
Aug 29, 2007·Drugs·Petros I RafailidisMatthew E Falagas
Jul 23, 2021·MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports·Kimberly A WorkowskiGail A Bolan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.